Lionheart Health, Inc. has been honored as the Top Implantable Stimulator Developer of the Year by MedTech Outlook, highlighting the company's work with KlothoImplant™ and MicroImplant™ technologies that utilize bioelectric signaling to control regenerative protein expression. This recognition underscores the potential of these technologies to offer new approaches for healthspan extension and organ regeneration through precise bioelectric signals that stimulate the body's natural regenerative processes.
The technologies are designed to deliver bioelectric signals that can stimulate stem cell homing, muscle building, blood vessel growth, and inflammation reduction. Brian Lasater, Chief Technology Officer at Lionheart Health, emphasized the potential of these micro implant stimulators to revolutionize treatment for various conditions by enabling on-demand protein release. The company's collaboration with Leonhardt Ventures LLC has expanded its bioelectric stimulation platform to target multiple organs and systems, including the heart, kidneys, and brain, with a portfolio ranging from benchtop stimulators to miniaturized implantable devices.
MedTech Outlook's recognition reflects the significant impact of Lionheart Health's innovations on the medical technology landscape. The company holds over 500 issued and pending patents, has multiple FDA clearances, and maintains a strong position in the XPRIZE Healthspan competition, positioning it at the forefront of developing healthcare solutions. For more information about Lionheart Health's technologies and achievements, visit https://www.LionheartLongevity.com, https://www.lionhearthealthstim.com, and https://www.LeonhardtVentures.com.
